Baseimmune

About Baseimmune

Baseimmune is a London-based biotech startup founded in 2019 that focuses on the development of novel and cross-protective vaccines. The company uses advanced computational approaches to design vaccines that can provide broad protection against various infectious diseases. This innovative approach was pioneered by the company's founders while they were at the Jenner Institute University of Oxford, and it has already resulted in two vaccine candidates currently in clinical trials.

Baseimmune serves a diverse range of clients, including healthcare providers and veterinary services. Its current pipeline includes two human vaccines against Malaria (BSI002) and a pancoronavirus vaccine (BSI001), as well as a veterinary vaccine against African Swine Fever (BSI001). These vaccines are being tested as mRNA/LNP or viral vectors, which are delivery systems used to introduce genetic material into cells.

The company operates in the global vaccine market, which is expected to grow significantly due to the ongoing COVID-19 pandemic and the increasing prevalence of various infectious diseases. Baseimmune's business model revolves around the research, development, and commercialization of its vaccines. The company generates revenue through the sale of its vaccines once they have been approved for use.

In October 2021, Baseimmune raised $4.8 million in seed funding to continue the development of its future-proof vaccines. This indicates that the company has strong financial backing and is well-positioned to continue its growth trajectory.